Skip to main content
SpringerLink
Log in

Safety of immunosuppression regimens compared

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Sampaio M, Shah T, Hutchinson I, Cho Y.Immunosupression and Risk for Post-Transplant Lymphoproliferative Disorder in Kidney Transplant Recipients. American Transplant Congress -- 11th Joint Congress of the American Society of Transplant Surgeons and the American Society of Transplantation: abstr. 243, 30 Apr 2011. Available from: URL: http://2011.atcmeeting.org

  2. Larsen C, Grinyo J, Pestana JM, Vanrenterghem Y, Vincenti F, Dong Y, Thomas D, Charpentier B.3-Year Safety Profile of Belatacept in Kidney Transplant Recipients from the BENEFIT and BENEFIT-EXT Studies. American Transplant Congress -- 11th Joint Congress of the American Society of Transplant Surgeons and the American Society of Transplantation: abstr. 228, 30 Apr 2011. Available from: URL: http://2011.atcmeeting.org

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Safety of immunosuppression regimens compared. React. Wkly. 1355, 4 (2011). https://doi.org/10.2165/00128415-201113550-00009

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201113550-00009

Keywords

Search

Navigation